ES2668861T3 - Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR - Google Patents
Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR Download PDFInfo
- Publication number
- ES2668861T3 ES2668861T3 ES13829184.4T ES13829184T ES2668861T3 ES 2668861 T3 ES2668861 T3 ES 2668861T3 ES 13829184 T ES13829184 T ES 13829184T ES 2668861 T3 ES2668861 T3 ES 2668861T3
- Authority
- ES
- Spain
- Prior art keywords
- nsclc
- egfr
- lung cancer
- scc
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 146
- 238000011282 treatment Methods 0.000 title claims abstract description 137
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 229940079593 drug Drugs 0.000 title claims abstract description 68
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 149
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 147
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 145
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 136
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract description 77
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 70
- 201000005202 lung cancer Diseases 0.000 claims abstract description 69
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 69
- 208000003849 large cell carcinoma Diseases 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 201000010968 pleomorphic carcinoma Diseases 0.000 claims abstract description 25
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 229960005395 cetuximab Drugs 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 29
- 238000011269 treatment regimen Methods 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 22
- 210000004072 lung Anatomy 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- -1 panitumumab Chemical compound 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- 229960000470 omalizumab Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- 238000011127 radiochemotherapy Methods 0.000 claims description 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical group C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 15
- 229940121647 egfr inhibitor Drugs 0.000 description 13
- 206010059866 Drug resistance Diseases 0.000 description 10
- 239000003446 ligand Substances 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 239000000092 prognostic biomarker Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 4
- 102100025498 Proepiregulin Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000011961 computed axial tomography Methods 0.000 description 4
- 229960005061 crizotinib Drugs 0.000 description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 101150029707 ERBB2 gene Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102200006538 rs121913530 Human genes 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 102100038778 Amphiregulin Human genes 0.000 description 2
- 101800001382 Betacellulin Proteins 0.000 description 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102100030323 Epigen Human genes 0.000 description 2
- 108010016906 Epigen Proteins 0.000 description 2
- 101800000155 Epiregulin Proteins 0.000 description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 2
- 101001056707 Homo sapiens Proepiregulin Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 102100029837 Probetacellulin Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229940122558 EGFR antagonist Drugs 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
- 101100043112 Homo sapiens SERPINB3 gene Proteins 0.000 description 1
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 description 1
- 208000016495 Horner Syndrome Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100036383 Serpin B3 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000001122 Superior Vena Cava Syndrome Diseases 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 208000016894 basaloid carcinoma Diseases 0.000 description 1
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000106 biosimilars Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003796 diagnosis of exclusion Methods 0.000 description 1
- 229940052354 dibasic sodium phosphate heptahydrate Drugs 0.000 description 1
- 238000002596 diffuse optical imaging Methods 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000006642 solid adenocarcinoma with mucin production Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012079399 | 2012-07-31 | ||
| WOPCT/CN2012/079399 | 2012-07-31 | ||
| PCT/US2013/053091 WO2014028221A1 (en) | 2012-07-31 | 2013-07-31 | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2668861T3 true ES2668861T3 (es) | 2018-05-22 |
Family
ID=50101405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13829184.4T Active ES2668861T3 (es) | 2012-07-31 | 2013-07-31 | Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9921222B2 (enExample) |
| EP (1) | EP2879712B1 (enExample) |
| JP (1) | JP6324381B2 (enExample) |
| ES (1) | ES2668861T3 (enExample) |
| WO (1) | WO2014028221A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017112960A (ru) * | 2014-09-16 | 2018-10-17 | Эббви Инк. | Велипариб в комбинации с карбоплатином и паклитакселом для лечения немелкоклеточного рака легких у курильщиков |
| TWI859118B (zh) * | 2017-03-29 | 2024-10-21 | 大陸商中美冠科生物技術（太倉）有限公司 | 測定對胃癌之西妥昔單抗（ｃｅｔｕｘｉｍａｂ）敏感性的系統及方法 |
| CN112813164A (zh) * | 2021-01-18 | 2021-05-18 | 四川省肿瘤医院 | Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2111870A1 (en) | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| EP1622941A2 (en) | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| WO2007001868A1 (en) | 2005-06-28 | 2007-01-04 | Genentech, Inc. | Egfr and kras mutations |
| WO2007058823A2 (en) | 2005-11-12 | 2007-05-24 | Eli Lilly And Company | Anti-egfr antibodies |
| WO2008140493A2 (en) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of Californina | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
| US20100009390A1 (en) | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| CN102164960A (zh) | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| WO2010080463A1 (en) | 2008-12-18 | 2010-07-15 | Imclone Llc | Antibody humanization |
| KR101108642B1 (ko) | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
| ES2639056T3 (es) | 2009-10-28 | 2017-10-25 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-EGFR y sus usos |
| EP2499486A4 (en) * | 2009-11-13 | 2013-11-27 | Infinity Pharmaceuticals Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER |
| CA2783715A1 (en) | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
| JP2011144124A (ja) | 2010-01-13 | 2011-07-28 | Fujirebio Inc | 活性型ｅｇｆｒ特異抗体 |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| CN105153307A (zh) | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
| US9029513B2 (en) | 2010-06-04 | 2015-05-12 | Toagosei Co. Ltd. | Anti-EGFR antibody and use thereof |
| WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
| WO2012020059A1 (en) | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Humanized egfr antibodies |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
-
2013
- 2013-07-31 ES ES13829184.4T patent/ES2668861T3/es active Active
- 2013-07-31 EP EP13829184.4A patent/EP2879712B1/en active Active
- 2013-07-31 US US14/418,684 patent/US9921222B2/en not_active Expired - Fee Related
- 2013-07-31 WO PCT/US2013/053091 patent/WO2014028221A1/en not_active Ceased
- 2013-07-31 JP JP2015525570A patent/JP6324381B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20150168411A1 (en) | 2015-06-18 |
| JP6324381B2 (ja) | 2018-05-16 |
| EP2879712A1 (en) | 2015-06-10 |
| WO2014028221A1 (en) | 2014-02-20 |
| JP2015527341A (ja) | 2015-09-17 |
| EP2879712B1 (en) | 2018-04-25 |
| US9921222B2 (en) | 2018-03-20 |
| EP2879712A4 (en) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pellat et al. | Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms | |
| ES3034910T3 (en) | Prostate cancer cell lines, gene signatures and uses thereof | |
| AU2007213920B2 (en) | Treatment of metastatic breast cancer | |
| ES2661238T3 (es) | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer | |
| WO2014028222A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
| JP2020040959A (ja) | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 | |
| CN110208535A (zh) | 基于caix分级的癌症治疗 | |
| US10085987B2 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| ES2668861T3 (es) | Marcadores histológicos para identificar pacientes con carcinoma de pulmón de células no pequeñas para el tratamiento con un fármaco anti EGFR | |
| ES3019582T3 (en) | Method for predicting efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-pd-1 antibody or anti-pd-l1 antibody therapy | |
| JP2017535548A (ja) | Ｖｅｇｆアンタゴニストの応答の予測 | |
| CN104168921B (zh) | 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物 | |
| CN105188742A (zh) | Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途 | |
| EP4352509A1 (en) | Combined treatment for cancer | |
| US20150218647A1 (en) | Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug | |
| Board | Ewing Sarcoma Treatment (PDQ®) | |
| Burns et al. | MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype | |
| WO2019012174A1 (es) | pEGFR Y FGFR1 Y/O FGFR4 PARA USO EN LA PREDICCIÓN DE LA RESPUESTA DE LOS PACIENTES A UN TRATAMIENTO DEL CÁNCER DE PULMÓN Y MÉTODO Y KIT BASADOS EN DICHO USO | |
| Jain et al. | CURRENT TREATMENT AND MANAGEMENT OF OROPHARYNGEAL CANCER: A REVIEW | |
| US20230375553A1 (en) | A ratio between plgf and sflt1 is predictive for neural invasion in patients suffering from pancreatic cancer | |
| Kemps et al. | Alk plus Histiocytosis: A new Clinicopathologic Spectrum highlighting Neurologic Involvement and Responses to Alk Inhibition | |
| Napolitano et al. | Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer | |
| ES2734485T3 (es) | Células progenitoras hematopoyéticas derivadas de la médula ósea y células progenitoras endoteliales como indicadores pronósticos para el cáncer | |
| CN105407913A (zh) | 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物 | |
| Blaszkowsky et al. | Case 13-2011: A 49-Year-Old Man with Adenocarcinoma of the Rectum |